TABLE 2.

Growth inhibition of B. subtilis strains in the presence of lincomycin, puromycin, and Hg2+

StrainRelevant genotypeIC50a
Lincomycin (μg/ml)Puromycin (μg/ml)Hg2+ (μM)
168Wild type8.5 ± 2.914.4 ± 5.17.2 ± 1.4
PLR21mrA(Q52P stop to S)106.6 ± 25.3474.6 ± 57.76.6 ± 1.3
PLR31mrA(Q52P stop to S) 1mrB::cat3.8 ± 0.57.3 ± 1.48.3 ± 2.1
PLR41mrA(Q52P stop to S) yxaG::pMUTIN2NDb464.6 ± 23.83.4 ± 1.1
PLR51mrA(Q52P stop to S) 1mrB::cat yxaG::pMUTIN2ND9.2 ± 0.89.5 ± 0.7
PLR61mrA(Q52P stop to S) yxaH::pMUTIN2ND468.4 ± 18.43.4 ± 1.1
PLR71mrA(Q52P stop to S) 1mrB::cat yxaH::pMUTIN2ND9.5 ± 0.910.2 ± 0.3
  • a IC50, concentration of the drug or ion that gave 50% growth inhibition. The values are mean ± standard deviations for at least four independent measurements.

  • b ND, not determined under the assay conditions employed, due to the presence of the pMUTIN2-borne erm gene (20), which is known to confer resistance to lincomycin, as well as erythromycin, on the cells.